Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab in MALT Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				IELSG19 NCT00210353

Last Modified: 12/15/2008 First Published: 12/20/2007


2.		Phase III Randomized Study of First-Line Therapy Comprising Chlorambucil Versus Fludarabine Phosphate in Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma With Villous Lymphocytes, or Non-IgM Lymphoplasmacytic Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				TSH-WM1 ISRCTN56052618, TSH-WM1, NCT00608374


3.		Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				WM1 NCT00566332


4.		Ofatumumab-Chlorambucil Combination vs. Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Approved-not yet active				18 and over				Pharmaceutical / Industry				OMB110911 EudraCT 2008-004932-19, NCT00748189


5.		Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				CR0506PI REC:05-054, NCT00558961


6.		Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				INST 1003C NCT00250718


7.		A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				MO20927 NCT00532129

First Published: 8/21/2008


8.		Phase II Study of Rituximab, Bortezomib, Doxorubicin Hydrochloride, Dexamethasone, and Chlorambucil as First-Line Therapy in Older Patients With Stage II-IV Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				65 to 80				Other				GOELAMS-MANTEAU-2006-SA MANTEAU 2006 SA, EUDRACT-2006-004768-30, INCA-RECF0475, NCT00740415


9.		A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				60 and over				Pharmaceutical / Industry				ML21445 2008-001612-20, NCT00738374

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute